Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Isis Pharmaceuticals reports final Phase 2 data on ISIS-GCGR RX showing reduction in HbA1c in Patients with Type 2 Diabetes


Monday, 16 Jun 2014 07:00am EDT 

Isis Pharmaceuticals Inc:Announces final results from Phase 2 study of ISIS-GCGRRxin patients with type 2 diabetes uncontrolled on stable metformin therapy.Patients in the per protocol population (PP) treated with ISIS-GCGRRx in addition to metformin achieved absolute mean reduction in hemoglobin A1c (HbA1c) of up to 2.25 percentage points from baseline after only 13 weeks of treatment.